301 results about "Open reading frame" patented technology

The invention discloses application of a wheat WRKY transcription factor gene TaWRKY1, and belongs to the technical field of gene engineering. A nucleotide sequence of an open reading frame of the gene TaWRKY1 is shown as SEQ ID NO: 1, and the gene TaWRKY1 is infected by stripe rust to induce expression in interaction of wheat and stripe rust, and plays a negative regulation role in wheat stripe rust resistance. A TaWRKY1 gene editing mutant plant is created by using an agrobacterium tumefaciens-mediated genetic transformation method, the sporulation quantity on wheat leaves of the gene editing mutant is obviously reduced, and the allergic necrosis is increased, which indicates that the edited gene TaWRKY1 can improve the resistance of wheat to stripe rust. The invention provides a disease-resistant germplasm resource for the cultivation of the stripe rust-resistant wheat variety.

This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5' untranslated region (UTR) and 3' UTR, particular 3' UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.

This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5′ untranslated region (UTR) and 3′ UTR, particular 3′ UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.

The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.

The invention discloses a rice sheath blight resistant adiponectin receptor OsPLS3 protein as well as an encoding protein and application thereof. The amino acid sequence of the rice adiponectin receptor OsPLS3 protein is as shown in SEQ ID NO. 3. The genome nucleotide sequence of the encoding gene of the rice adiponectin receptor gene OsPLS3 is as shown in SEQ ID NO.1, and the nucleotide sequence of the open reading frame of the rice adiponectin receptor gene OsPLS3 is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the rice adiponectin receptor gene OsPLS3. Experiments prove that after the rice adiponectin receptor gene OsPLS3 is over-expressed in rice, the resistance of the rice to sheath blight can be improved, and after the rice adiponectin receptor gene OsPLS3 is knocked out, the rice adiponectin receptor gene OsPLS3 is more susceptible to rhizoctonia solani, namely, the resistance of the rice to the sheath blight is positively regulated by the OsPLS3. The rice adiponectin receptor gene OsPLS3 provided by the invention has an important production value for rice sheath blight resistance breeding.

Recombinant adenovirus genomes that include an exogenous open reading frame (ORF) and a self-cleaving peptide coding sequence are described. Optimal placement of the exogenous genes for minimal impact on viral kinetics is further disclosed. Therapeutic applications of the recombinant adenoviruses are also described.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.

The invention discloses a wheat stripe rust effect protein gene Pst4593 and application thereof, and belongs to the technical field of gene engineering. A nucleotide sequence of an open reading frame of the wheat stripe rust effect protein gene Pst4593 is shown as SEQ ID NO: 1, the gene positively regulates pathogenicity of stripe rust to wheat, silence of the wheat stripe rust effect protein gene Pst4593 can improve resistance of wheat to stripe rust, and relative expression quantities of wheat related defense genes TaPR1, TaPR2 and TaPR5 are remarkably improved. The wheat stripe rust effect protein gene Pst4593 is related to induced expression of stripe rust aspirator, and the protein coded by the wheat stripe rust effect protein gene Pst4593 also has lipase activity and can influence pathogenicity of stripe rust. The invention provides a disease-resistant germplasm resource for the cultivation of the stripe rust-resistant wheat variety.

The present invention provides a method for computer analysis of a genome of a plant subject, comprising identifying a plurality of sequences that collectively define a promoter set of the plant subject, where each sequence within the promoter set consists of an expression control region, the expression control region extends from an initiation codon of an open reading frame to about 100 kilobases away from the 5'and / or 3 'end of the initiation codon. A transcriptome in the form of mRNA expression data of a plant subject is obtained and analyzed using a sequence-based modeling algorithm to provide a predicted value of the expression level of each protein coding gene within the transcriptome and associate this value with the sequence of the corresponding expression control region within the promoter group. The method can be used to generate new designs for expression control sequences, which are most likely to provide the desired expression profile for operably linked coding sequences. Nucleic acid libraries, plant cells, plant tissues and plants comprising the novel expression control sequences are also provided.

A method of producing a population of mature human pluripotent stem cell-derived sensory neurons (hPSC-SNs) expressing a target gene associated with at least one of nociceptive pain, chronic pain, pruriception and a nociceptive- or pruriceptive- mediated condition, the method comprising introducing into a population of human pluripotent stem cells (hPSCs) a composition comprising at least one site-directed nuclease targeting a site within the target gene, and at least one nucleic acid comprising a nucleotide sequence encoding at least one screenable, selectable marker that is flanked by (i) a nucleotide sequence homologous with a region located upstream of the target site within the target gene and (ii) a nucleotide sequence homologous with a region located downstream of the target site within the target gene, wherein the target site is located downstream of the open reading frame of the target gene, and wherein the site-directed nuclease cleaves the target site of the target gene and the nucleic acid encoding the screenable, selectable marker is inserted at the target site; covering said population of hPSCs under an extracellular matrix comprising at least one neuronal differentiation driver to produce a sensory committed neural crest population; contacting said sensory committed neural crest population with at least one neuronal differentiation driver and at least one neurotrophic factor to produce a population of early sensory neurons (SNs); and contacting said population of early SNs with at least one neurotrophic factor to produce a population of mature hPSC-SNs expressing at least one of SN marker or one pan neuronal marker; isolating the cells expressing the at least one screenable, selectable marker, wherein said population of mature hPSC-SNs expressed said one target gene associated with nociceptive pain, chronic pain, pruriception a nociceptive- or pruriceptive- mediated condition, and wherein said population of mature hPSC-SNs responds to a nociceptive and pruriceptive stimulus.

The invention relates to a method for stimulating an immune response by intramuscular injection of an artificial nucleic acid molecule comprising an open reading frame encoding an antigen and a 3′-UTR comprising at least two poly(A) sequences. The method may yield an increased immune response to the antigen or an increased neutralizing antibody response to the antigen.

Synthetic RNA molecules comprising at least two RNA-binding protein (RBP)-binding motifs, wherein the at least two RBP-binding motifs bind the same first RBP and comprise non-identical sequences are provided. Synthetic RNA molecules comprising an RBP-binding motif that binds two orthogonal RBPs, comprising at least three RBP-binding motifs for three orthogonal RBPs or comprising a first RBP-binding motif, a second RBP-binding motif, a regulatory element and an open reading frame wherein the first and second RBP-binding motifs cooperatively enhance translation of the open reading frame are also provided. Compositions, cells and methods of use or generating the synthetic RNA molecules are also provided.

The invention relates to an artificial nucleic acid molecule comprising at least one 5′ UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and / or a 3′ UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and / or genetic vaccination.

The invention relates to the field of genetic engineering, in particular to an optimized bacillus subtilis expression vector, a genetically engineered bacterium containing the expression vector and application of the genetically engineered bacterium. The vector is based on pMA5 plasmids, and a shuttle type bacillus subtilis expression vector is optimized; an open reading framework with unknown functions in the bacillus subtilis expression vector is reduced, so that the size of the vector is reduced, the expression burden of cells is reduced, and an optimization effect is achieved; the optimized bacillus subtilis expression vector not only can be stably copied in escherichia coli, but also can be stably expressed in bacillus subtilis, and the expression level of heterologous gene coding protein is improved by utilizing the genetically engineered bacteria containing the optimized bacillus subtilis expression vector.

Provided are a replicable RNA molecule and uses thereof, the present invention relates to a replicable RNA molecule comprising, from the 5'end to the 3 'end, a 5' cap, a 5 'UTR, an open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3' UTR, and a poly (A) tail wherein the RNA replicase is capable of amplifying the replicable RNA molecule and an RNA molecule containing the sequence of interest and the 3 'UTR wherein the RNA replicase is derived from the group consisting of the group consisting of the MosdPedras virus, MDPV, EVEV, Riogro virus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus and Mycovirus. RnV, Muslim virus, MUCV, Highland J virus, PIXV, TROV, Cabassu virus, TONV, Bebaru virus, BEBV, Formun virus, GETV, or Nnumu virus, and NDUV can be used in the treatment of a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, and a disease.

The invention discloses an aspergillus oryzae engineering bacterium as well as a construction method and application of the aspergillus oryzae engineering bacterium, and relates to the technical field of genetic engineering. The method comprises the following steps of: (a) connecting and fusing an open reading frame of an endogenous gene with a fungal laccase copper oxidoreductase structural domain and a target heterologous protein gene through a dual-basic amino acid endopeptidase cleavage site gene; or connecting and fusing an open reading frame of an endogenous gene with a multi-copper oxidase structural domain and a target heterologous protein gene through a dual-basic amino acid endopeptidase cleavage site gene; and (b) at least one of a gene Aovps10, a gene AosedD and a gene Aoemp47 is knocked out. The aspergillus oryzae engineering bacterium provided by the invention can realize high-efficiency expression of the heterologous protein, and the extracellular yield of the heterologous protein is obviously improved.

This disclosure provides improved RNA molecules, including mRNA molecules that can be produced by in vitro transcription and are suitable for in vivo transfection using an appropriate delivery vehicle, such as a lipid nanoparticle (LNP) or targeted lipid nanoparticle (tLNP). The improved RNA include particular combinations of 5' untranslated region (UTR) and 3' UTR, particular 3' UTRs, or particular open reading frame sequences. Also provided herein are compositions of the LNP, or tLNP with an antibody as a targeting moiety, such as anti-CD8 antibodies that are used as targeting moiety.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The present invention generally relates to tRNA-based effector molecules for use in inserting missense mutations into the open reading frame (ORF) of a gene, e.g., for the treatment of repetitive sequence amplification diseases.

The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

The present invention provides a pharmaceutical composition for treating cancer, the pharmaceutical composition comprising a nucleic acid that suppresses the expression of Chromosome 11 Open Reading Frame 97 (C11orf97). With the present invention, it becomes possible to treat cancer.

The present invention encompasses engineered meganucleases which recognize and cleave a recognition sequence within an open reading frame (ORF) of the genome of at least two genotypes of the Hepatitis B virus (HBV). The present invention also encompasses methods of using such engineered meganucleases in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infection, or treating hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, nucleic acids encoding engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.

Disclosed herein are a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding a protein of interest, a heterologous 5' untranslated region (UTR) and / or a heterologous 3' UTR for highly expressing the protein of interest. A method for synthesizing the mRNA and uses of the mRNA are also provided.

This invention relates to polynucleotides comprising UBE3A open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a UBE3A gene or aberrant activity of a UBE3A gene product in the subject, such as Angelman Syndrome.

The invention relates to the field of biology, and particularly provides a replication-deficient influenza virus vaccine skeleton which comprises a PA gene, an HA gene, an NP gene, an NA gene, an M gene, an NS gene and a PB2 gene of an influenza virus. The PB2 gene is replaced into a PB1 gene coding region of a vaccine skeleton; the open reading frame of the original PB2 gene can be replaced by an exogenous gene, so that the exogenous gene is inserted into the vaccine skeleton and expressed. The skeleton has the advantages that the capacity is large, the antigen can be efficiently and stably expressed, the passage is stable, and the like. Meanwhile, the invention also discloses a replication-defective influenza virus as well as a preparation method and application thereof.

Provided herein are a respiratory syncytial virus (RSV) vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding RSV mutant F B strain protein, and optionally a mRNA including an ORF encoding RSV mutant F A strain protein, and a method of inducing immune response against RSV by administering an effective amount of the RSV vaccine composition to a subject in need thereof. Provided herein are also a respiratory syncytial virus (RSV) and human metapneumovirus virus (hMPV) vaccine composition including a mRNA including an ORF encoding RSV mutant F A strain protein, a mRNA including an ORF encoding RSV mutant F B strain protein, and a mRNA including an ORF encoding hMPV F protein, and a method of inducing immune response against RSV and hMPV by administering an effective amount of the RSV and hMPV vaccine composition to a subject in need thereof.

Described herein are methods and compositions for accurate detection of cancer using ultrasensitive immunoassays, e.g., digital ELISA, to detect open reading frame 1 protein (ORF1p), which is encoded by the LINE-1 retrotransposon, in biofluids.

The present disclosure provides transcription factors and methods for stem cell differentiation into hepatocytes or hepatic cells. In some examples, a pluripotent stem cell (PSC) comprises a nucleic acid. In some examples, the nucleic acid comprises an open reading frame encoding one or more transcription factors, one or more transcription factors, or an activator of transcription of the open reading frame encoding one or more transcription factors. In some examples, the nucleic acid comprising an open reading frame encoding one or more transcription factors, the one or more transcription factors, or the activator of transcription of the open reading frame encoding one or more transcription factors induces differentiation of the PSC into a hepatocyte or a hepatic cell.